JCB, Volume 9, Number 4, 2003 Editorial Vol.9 No. 4 (2003) Editorial: Yin, yang and the biopharmaceutical industry Henry I Miller   Commentary Vol.9 No. 4 (2003) Opinion piece: Biotechnology's growth–innovation paradox and the new model for success Ann Baker Biotechnology companies are increasingly challenging traditional pharmaceutical companies as the discoverers, developers and marketers of drugs. The biotechnology secto Article Vol.9 No. 4 (2003) Life after Enron and ImClone: Special concerns for the biotechnology company Neil H Aronson The recent enactment of federal legislation and the ongoing adoption of comprehensive regulations by the Securities and Exchange Commission (SEC) and stock exchanges cr Article Vol.9 No. 4 (2003) The key to successful collaborations: Rigorous and independent due diligence Ian Rhodes In a maturing bio-pharma industry and with capital markets closed, collaboration is becoming the main route for companies to achieve the critical mass and cash flow nec Article Vol.9 No. 4 (2003) Dominating global intellectual property: Overview of patentability in the USA, Europe and Japan Thomas J Kowalski The USA, Europe and Japan dominate intellectual property. The patent offices of these three economies issue the vast majority of the world's patents and harmonisation h Article Vol.9 No. 4 (2003) Patent issues and future trends in drug development Faiz Kermani The global biopharmaceutical industry has been one of the most productive and profitable industrial sectors; however, the drug development process remains risky and exp Article Vol.9 No. 4 (2003) Strategies for building a global healthcare biotechnology company James A Geraghty This paper looks at the challenges, opportunities and strategies involved in building a global biotechnology company. There is no single global strategy that will answe Article Vol.9 No. 4 (2003) Regulatory Submissions Trends Survey 2002 Ellen Semple This Regulatory Submissions Trends Survey, conducted by CDC Solutions in December 2002, takes the first steps to gauge how regulatory departments of US and European lif Article Vol.9 No. 4 (2003) Marketspace: Trends in biotherapeutics Alex K Pavlou Analysis of the leading and emerging biotechnology companies identifies current and future trends in biotherapeutics. The ten leading biotechnology companies are foreca Legal and Regulatory Updates Vol.9 No. 4 (2003) Legal and regulatory update: Voluntary withdrawal of marketing authorisations and consequences for parallel importers John Wilkinson When a reference marketing authorisation is withdrawn for reasons unconnected with the protection of health, as in cases C-15/01 and C-113/01, it is not acceptable that Legal and Regulatory Updates Vol.9 No. 4 (2003) EU Financial accounts reports David Citron  Â